Clinical trials: Uveitis; Posterior, Disorder
- Condition Uveitis; Posterior, Disorder
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Uveitis, Posterior, Uveitis, Intermediate
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- LUMINATE (NCT00404742)
- Testing
- LX211
- Where
- 41 sites in United States, Austria and 5 more
- Volunteers
- 232 people
- Sponsor
- Lux Biosciences, Inc.
Uveitis
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
This study evaluates the long- term safety and effectiveness of adalimumab in participants with non-infectious intermediate-, posterior-, or pan-uveitis in daily practice in Japan.
- Trial name
- NCT02916017
- Where
- 39 sites in Japan
- Volunteers
- 259 people
- Sponsor
- AbbVie
Diabetes, Macular Edema
Research Study in Patients With Persistent Macular Edema
The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods.
- Conditions
- Diabetes, Macular Edema, Diabetic Retinopathy, Retinal Disease
- Trial name
- NCT00035906
- Testing
- DEX PS DDS®
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Allergan
Uveitis, Posterior
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Fluocinolone Acetonide Intravitreal Implant
- Trial name
- NCT03145025
- Testing
- Retisert, Fluocinolone Acetonide Intravitreal Implant
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Uveitis, Posterior, Uveitis, Intermediate
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- LUMINATE (NCT00404612)
- Testing
- LX211
- Where
- 41 sites in United States, Austria and 5 more
- Volunteers
- 218 people
- Sponsor
- Lux Biosciences, Inc.